Financing ·
Inhibrx Biosciences, Inc. entered into a second amendment to its loan and security agreement with Oxford Finance LLC…
INBXInhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. entered into a second amendment to its loan and security agreement with Oxford Finance LLC, expanding the total credit facility to $500.0 million. The amendment includes a $325.0 million additional tranche consisting of a $100.0 million Term C Loan, which was immediately funded, and a potential $225.0 million Term D Loan. As part of the Term C funding, the company issued warrants to purchase 21,457 shares of common stock at an exercise price of $93.21 per share. Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates.